AAPL   321.85 (+1.23%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
GE   6.76 (+2.89%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
DIS   118.77 (+1.25%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
AAPL   321.85 (+1.23%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
GE   6.76 (+2.89%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
DIS   118.77 (+1.25%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
AAPL   321.85 (+1.23%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
GE   6.76 (+2.89%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
DIS   118.77 (+1.25%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
AAPL   321.85 (+1.23%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
GE   6.76 (+2.89%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
DIS   118.77 (+1.25%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
Log in

NASDAQ:GBTGlobal Blood Therapeutics Stock Price, Forecast & News

$68.67
-1.25 (-1.79 %)
(As of 06/1/2020 04:00 PM ET)
Add
Compare
Today's Range
$67.00
Now: $68.67
$70.55
50-Day Range
$65.08
MA: $72.74
$81.82
52-Week Range
$39.95
Now: $68.67
$87.54
Volume1.00 million shs
Average Volume937,447 shs
Market Capitalization$4.18 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.9
Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.
Read More
Global Blood Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GBT
CUSIPN/A
Phone650-741-7700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.11 million
Book Value$9.61 per share

Profitability

Net Income$-266,770,000.00

Miscellaneous

Employees171
Market Cap$4.18 billion
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive GBT News and Ratings via Email

Sign-up to receive the latest news and ratings for GBT and its competitors with MarketBeat's FREE daily newsletter.

Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions

How has Global Blood Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Global Blood Therapeutics' stock was trading at $54.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GBT stock has increased by 25.2% and is now trading at $68.67. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Global Blood Therapeutics?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Global Blood Therapeutics.

When is Global Blood Therapeutics' next earnings date?

Global Blood Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Global Blood Therapeutics.

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics Inc (NASDAQ:GBT) posted its quarterly earnings data on Wednesday, May, 6th. The company reported ($1.20) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.47) by $0.27. The business earned $14.12 million during the quarter, compared to analyst estimates of $3.65 million. During the same period last year, the business posted ($0.87) earnings per share. View Global Blood Therapeutics' earnings history.

What price target have analysts set for GBT?

16 brokerages have issued 1 year price targets for Global Blood Therapeutics' shares. Their forecasts range from $60.00 to $150.00. On average, they expect Global Blood Therapeutics' share price to reach $105.13 in the next year. This suggests a possible upside of 53.1% from the stock's current price. View analysts' price targets for Global Blood Therapeutics.

Has Global Blood Therapeutics been receiving favorable news coverage?

Media coverage about GBT stock has trended very positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Global Blood Therapeutics earned a coverage optimism score of 3.5 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutGlobal Blood Therapeutics.

Are investors shorting Global Blood Therapeutics?

Global Blood Therapeutics saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 9,450,000 shares, a drop of 6.4% from the April 30th total of 10,100,000 shares. Based on an average trading volume of 972,400 shares, the short-interest ratio is currently 9.7 days. Approximately 15.9% of the shares of the company are short sold. View Global Blood Therapeutics' Current Options Chain.

Who are some of Global Blood Therapeutics' key competitors?

What other stocks do shareholders of Global Blood Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Cynosure (CYNO), TherapeuticsMD (TXMD), Exelixis (EXEL), AbbVie (ABBV), Advanced Micro Devices (AMD), Square (SQ) and Vertex Pharmaceuticals (VRTX).

Who are Global Blood Therapeutics' key executives?

Global Blood Therapeutics' management team includes the following people:
  • Dr. Ted W. Love, Pres, CEO & Director (Age 60)
  • Dr. Charles J. Homcy, Founder, Advisor & Director (Age 71)
  • Mr. Jeffrey S. Farrow, Chief Financial Officer (Age 57)
  • Mr. Peter Radovich, Sr. VP of Operations (Age 41)
  • Dr. Hing Sham, Sr. VP of Research (Age 67)

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an IPO on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

Who are Global Blood Therapeutics' major shareholders?

Global Blood Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (9.95%), BlackRock Inc. (7.84%), Janus Henderson Group PLC (7.47%), Wellington Management Group LLP (4.54%), State Street Corp (3.59%) and Capital World Investors (2.38%). Company insiders that own Global Blood Therapeutics stock include De Dominicis Robert, Deval L Patrick, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Mark L Perry, Philip A Pizzo, Ted W Love, Tricia Borga Suvari and Willie L Jr Brown. View institutional ownership trends for Global Blood Therapeutics.

Which institutional investors are selling Global Blood Therapeutics stock?

GBT stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Wellington Management Group LLP, Franklin Resources Inc., Frontier Capital Management Co. LLC, BlackRock Inc., Two Sigma Advisers LP, Fernwood Investment Management LLC, and Wells Fargo & Company MN. Company insiders that have sold Global Blood Therapeutics company stock in the last year include Deval L Patrick, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Mark L Perry, Philip A Pizzo, Ted W Love, and Tricia Borga Suvari. View insider buying and selling activity for Global Blood Therapeutics.

Which institutional investors are buying Global Blood Therapeutics stock?

GBT stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Capital World Investors, TimesSquare Capital Management LLC, Peregrine Capital Management LLC, Perceptive Advisors LLC, JPMorgan Chase & Co., Morgan Stanley, and Morgan Stanley. View insider buying and selling activity for Global Blood Therapeutics.

How do I buy shares of Global Blood Therapeutics?

Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Global Blood Therapeutics' stock price today?

One share of GBT stock can currently be purchased for approximately $68.67.

How big of a company is Global Blood Therapeutics?

Global Blood Therapeutics has a market capitalization of $4.18 billion and generates $2.11 million in revenue each year. The company earns $-266,770,000.00 in net income (profit) each year or ($4.71) on an earnings per share basis. Global Blood Therapeutics employs 171 workers across the globe.

What is Global Blood Therapeutics' official website?

The official website for Global Blood Therapeutics is www.gbt.com.

How can I contact Global Blood Therapeutics?

Global Blood Therapeutics' mailing address is 181 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.